Examkin

Soru

Zorluk: OrtaImmunologic and Inflammatory Processes

A 24-year-old woman presents to the emergency department with the acute onset of severe, colicky abdominal pain and progressive swelling of her upper lip. The symptoms began 3 hours ago, shortly after a minor dental extraction. She has a history of recurrent, unexplained episodes of severe abdominal pain since adolescence, for which she has undergone multiple non-diagnostic evaluations. She has no history of food or drug allergies. Her only medication is a combined oral contraceptive pill. Vital signs are temperature 37.1°C (98.8°F), heart rate 98/min, blood pressure 118/76 mmHg, and respiratory rate 16/min. Physical examination reveals asymmetric, non-pitting edema of the upper lip and periorbital soft tissue. There is no urticaria, and the lungs are clear to auscultation bilaterally. Laboratory testing reveals a markedly decreased C4 level with a normal C3 level. Which of the following is the most appropriate next step in the management of this patient's acute symptoms?

  1. A
    Administration of an alpha-1, beta-1, and beta-2 adrenergic receptor agonist
  2. Administration of a bradykinin B2 receptor antagonistCevap
  3. C
    Administration of an intravenous histamine H1 receptor antagonist
  4. D
    Computed tomography imaging of the abdomen and pelvis with intravenous contrast
  5. E
    Administration of systemic corticosteroids and transition to a daily angiotensin-converting enzyme inhibitor

Cevap

The most appropriate next step is the administration of a bradykinin B2 receptor antagonist.
The correct answer involves administering a bradykinin B2 receptor antagonist. The patient's presentation of non-pitting facial edema without urticaria, recurrent unexplained abdominal pain, and symptom onset after dental trauma is characteristic of hereditary angioedema (HAE). The laboratory findings of a markedly decreased C4 level with a normal C3 level confirm the diagnosis. HAE is caused by a deficiency or dysfunction of the C1 esterase inhibitor, leading to unregulated activation of kallikrein and overproduction of bradykinin. Bradykinin acts on B2 receptors to cause potent vasodilation and increased vascular permeability. Acute attacks must be treated with targeted therapies such as a bradykinin B2 receptor antagonist (e.g., icatibant), a kallikrein inhibitor (e.g., ecallantide), or purified C1-INH concentrate.

Adım Adım Çözüm

1
Analyze the patient's clinical presentation and history.
The combination of non-pitting facial edema without urticaria, recurrent unexplained abdominal pain, and onset following dental trauma strongly suggests hereditary angioedema (HAE).
HAE classically presents with episodes of cutaneous angioedema, intense abdominal pain (due to bowel wall edema), and can be triggered by stress or tissue trauma (e.g., dental procedures).
2
Interpret the specific laboratory findings.
A markedly decreased C4 level with a normal C3 level confirms the diagnosis of a C1 esterase inhibitor (C1-INH) deficiency.
C1-INH deficiency leads to uninhibited autoactivation of C1, which continuously consumes C4. C3 remains normal because the classical pathway C3 convertase is unstable without adequate immune complex formation.
3
Identify the underlying pathophysiologic mediator and select targeted therapy.
HAE is mediated by excess bradykinin. The most appropriate acute targeted therapy is a bradykinin B2 receptor antagonist (icatibant), a kallikrein inhibitor, or C1-INH concentrate.
Standard allergic therapies (epinephrine, antihistamines, corticosteroids) target IgE- and histamine-mediated pathways and are entirely ineffective in bradykinin-mediated angioedema.

Anahtar Kavram

Hereditary angioedema is a bradykinin-mediated condition due to C1 esterase inhibitor deficiency, characterized by normal C3 and low C4 levels, and treated acutely with bradykinin B2 receptor antagonists, kallikrein inhibitors, or C1-INH replacement.
Bu soruyu puanla

Konular

Immunologic and Inflammatory Processes

Bu konudan daha fazla soru